News | April 19, 2022
Akron Bio completes plasmid DNA manufacturing facility
The facility will support clinical development by securing supply that will address the critical demand in the gene therapy and vaccine markets
The facility will support clinical development by securing supply that will address the critical demand in the gene therapy and vaccine markets
All intellectual-property disputes related to the market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved
The mAbxience partnership will enable Cipla to continue its ethos of ensuring equitable access to affordable, life-saving medication
Veritaz has over 40 brands marketed across the acute and critical care therapeutic segments
Additional data across neurological disorders, including Alzheimer’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatment
Digital meetings driving international partnering at CPhI Japan as companies search for ingredients suppliers
The Gujarat Biotechnology policy released last month has made radical changes to position the state as a biotechnology hub. It already has a thriving ecosystem of pharma companies and varied suppliers
Investment in technology and people and a meaningful industry-academia partnership can fuel the growth of the Indian biopharma sector
Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward
Pankaj Patel, Chairman, Zydus Lifesciences; Umang Vohra, CEO, Cipla; G V Prasad, Co-Chairman, Dr Reddy's; Nilesh Gupta, MD, Lupin and Dilip Shanghvi, MD, Sun Pharmaceuticals sharing their vision to outline the roadmap for the industry.
Subscribe To Our Newsletter & Stay Updated
